CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced promising study results that demonstrate the activation of CD4+ and CD8+ ...
For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...
Please provide your email address to receive an email when new articles are posted on . The odds of tissues harboring HIV DNA and viral DNA copies in those tissues were significantly lower in people ...
The MarketWatch News Department was not involved in the creation of this content. Strategy May Bolster Blood Cancer Therapy and Move HIV Research Closer to a Cure BRONX, N.Y., March 13, 2026 ...
Please provide your email address to receive an email when new articles are posted on . Postmenopausal women with HIV had higher levels of immune activation than premenopausal women with HIV, ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that the U.S. Military HIV Research Program (MHRP) at the Walter Reed ...
This study was aimed at investigating the development of T cell-mediated immune response in B cell tumor patients and at defining the optimal conditions for developing adoptive immunotherapy protocols ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results